Nasdaq
AnPac Bio Receives Nasdaq Delisting Notice
The Chinese cancer diagnostics firm plans to appeal the decision, which is related to a requirement that the firm maintain a minimum $2.5 million stockholders' equity.
Genetron Regains Compliance With Nasdaq Listing Requirement
The Chinese cancer molecular profiling firm had previously failed to meet the Nasdaq's minimum bid price requirement.
Sema4 Receives Nasdaq Noncompliance Warning, Will Return $42M Under Payor Lawsuit Settlement
The company's stock price had been below $1 per share for 30 trading days prior to the notice, which Sema4 received Dec. 28.
HTG Molecular Diagnostics to Implement Reverse Stock Split
Last month, the company reported a 48 percent year-over-year drop in third quarter revenues as it repositions itself as a developer of drug discovery technologies.
Centogene Gets Nasdaq Non-Compliance Notice
The company has 180 days from the date of the notice to regain compliance with the listing requirement, during which time it will continue to trade on the exchange.
Sep 27, 2022
AnPac Bio Inks Deal for $3.7M Investment
Sep 12, 2022
AnPac Bio Receives Nasdaq Delisting Determination
Aug 30, 2022
T2 Biosystems Regains Nasdaq Listing Requirements
Mar 28, 2022
AnPac Bio Receives Nasdaq Delisting Notice
Jan 25, 2022
AnPac Bio Warned by Nasdaq Over Listing Requirement
Sep 16, 2021
Hong Kong-Based Prenetics to go Public via SPAC
Aug 27, 2021
SeqLL to Go Public in $13M IPO
Jan 19, 2021
Lucira Health Files for $115M IPO
Sep 11, 2020
10x Genomics Prices Upsized $440M Public Offering
Aug 25, 2020